Quantitative assessment of tumor immune microenvironment in context of HER2 expression in MIBC
- 1Hospital of the University of Pennsylvania
Abstract
Muscle-invasive bladder cancer (MIBC) carries high risks of relapse and death despite contemporary care. In this study we aimed to evaluate whether the pretreatment immune microenvironment varied with HER2 status and if the differences influenced the response to neoadjuvant chemotherapy (NAC) and survival. We conducted a retrospective study of 62 treatment-naive MIBC patients diagnosed on pretreatment transurethral resection of bladder tumor (TURBT) specimens collected between 2008 and 2024. All patients received NAC followed by radical cystectomy. HER2 immunohistochemistry (IHC) was scored 0/1+/2+/3+ using gastroesophageal criteria. PD-L1 was assessed by combined positive score (CPS). CD3, CD20, and CD68 cell densities were quantified by digital image analysis. Overall survival was measured from the date of TURBT. HER2 IHC scores were 2+/3+ in 28 of 62 tumors (45%) and 0/1+ in 34 (55%). All seven IHC 2+ tumors lacked ERBB2 amplification by fluorescence in situ hybridization (FISH). NAC response occurred in 11 of 34 tumors with HER2 IHC 0/1+ (32%) and 9 of 28 tumors with HER2 IHC 2+/3+ (32%) (P = 1.00). PD-L1 expression was not associated with HER2 status. Immune-cell analyses showed trends toward higher CD3+ T-cell density, CD20+ B-cell density, and TM ratio in NAC responders, but no significant differences by HER2 status or combined PD-L1/HER2 subgroup status. After Bonferroni correction for multiple comparisons, none of the immune-cell metrics remained statistically significant. Overall survival did not differ between the HER2 IHC groups (P = 0.71). These findings indicate that HER2 IHC 2+/3+ expression is present in a substantial subset of MIBC but is not associated with NAC response or overall survival in this cohort. Further study is warranted to define the clinical relevance of MIBC with HER2 IHC 2+/3+ and its potential role in HER2-directed therapeutic strategies.
Related
- Expression, prognostic association, and immune microenvironment correlates of C4orf50 in breast cancer: a The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) bioinformatics study
- 1161 Novel IL1RAP expression gradient modulates the myeloid cell phenotype and T-cell infiltration patterns of the Ewing sarcoma immune microenvironment
- Differential expression of LYZ across pan-cancer and its prognostic value and immune microenvironment regulatory mechanisms in glioma
- Tissue Factor Expression Is Associated with Distinct Pattern of Immune-Cell Infiltration in the Ovarian Tumor Microenvironment
- Regional reproducibility of immune expression programs in glioblastoma and implications for single-biopsy assessment
BibTeX
@misc{du2026quantitative,
title = {{Quantitative assessment of tumor immune microenvironment in context of HER2 expression in MIBC}},
author = {W. Du and S. Koga and R. Pratap Nair and R. Tondon and P. Zhang and R. Puthiyaveettil and L. Mei and P. Lal},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.14.26363035},
url = {https://www.medrxiv.org/content/10.64898/2026.09.14.26363035v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Quantitative assessment of tumor immune microenvironment in context of HER2 expression in MIBC
AU - W. Du
AU - S. Koga
AU - R. Pratap Nair
AU - R. Tondon
AU - P. Zhang
AU - R. Puthiyaveettil
AU - L. Mei
AU - P. Lal
PY - 2026
DA - 2026/09/14
PB - medRxiv
DO - 10.64898/2026.09.14.26363035
UR - https://www.medrxiv.org/content/10.64898/2026.09.14.26363035v1
AB - Muscle-invasive bladder cancer (MIBC) carries high risks of relapse and death despite contemporary care. In this study we aimed to evaluate whether the pretreatment immune microenvironment varied with HER2 status and if the differences influenced the response to neoadjuvant chemotherapy (NAC) and survival. We conducted a retrospective study of 62 treatment-naive MIBC patients diagnosed on pretreatment transurethral resection of bladder tumor (TURBT) specimens collected between 2008 and 2024. All patients received NAC followed by radical cystectomy. HER2 immunohistochemistry (IHC) was scored 0/1+/2+/3+ using gastroesophageal criteria. PD-L1 was assessed by combined positive score (CPS). CD3, CD20, and CD68 cell densities were quantified by digital image analysis. Overall survival was measured from the date of TURBT. HER2 IHC scores were 2+/3+ in 28 of 62 tumors (45%) and 0/1+ in 34 (55%). All seven IHC 2+ tumors lacked ERBB2 amplification by fluorescence in situ hybridization (FISH). NAC response occurred in 11 of 34 tumors with HER2 IHC 0/1+ (32%) and 9 of 28 tumors with HER2 IHC 2+/3+ (32%) (P = 1.00). PD-L1 expression was not associated with HER2 status. Immune-cell analyses showed trends toward higher CD3+ T-cell density, CD20+ B-cell density, and TM ratio in NAC responders, but no significant differences by HER2 status or combined PD-L1/HER2 subgroup status. After Bonferroni correction for multiple comparisons, none of the immune-cell metrics remained statistically significant. Overall survival did not differ between the HER2 IHC groups (P = 0.71). These findings indicate that HER2 IHC 2+/3+ expression is present in a substantial subset of MIBC but is not associated with NAC response or overall survival in this cohort. Further study is warranted to define the clinical relevance of MIBC with HER2 IHC 2+/3+ and its potential role in HER2-directed therapeutic strategies.
ER -